Author: Wuxi Biologics

Posted Date:

May 12, 2026

WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index

Wuxi Biologics

May 12, 2026
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access

Wuxi Biologics

April 29, 2026
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival

Wuxi Biologics

April 24, 2026
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

Wuxi Biologics

April 23, 2026
WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year

Wuxi Biologics

April 17, 2026
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing

Wuxi Biologics

April 14, 2026
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

Wuxi Biologics

March 30, 2026
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture

Wuxi Biologics

March 25, 2026
WuXi Biologics Reports Record 2025 Annual Results

Wuxi Biologics

March 24, 2026
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

Wuxi Biologics

March 21, 2026